Aerovate Therapeutics shares dropped 90.4% following the release of Phase 2b trial results for AV-101 for pulmonary arterial hypertension. Despite being well tolerated, AV-101 failed to meet primary and secondary endpoints. Enrollment for Phase 3 is halted.
U.S. stocks were higher, with the Nasdaq Composite gaining over 100 points on Friday. Shares of Ermenegildo Zegna N.V. (NYSE: ZGN) fell sharply during Friday’s session as the company reported FY23 financial results.
Potential short squeeze plays gained steam in 2021 and continued through 2022, with new traders looking for the next huge move. High short interest and a high cost to borrow are among the common traits that could lead to a short squeeze.
Potential short squeeze plays gained steam in 2021 and have continued to attract attention, with new traders looking for the next huge move. High short interest and a high cost to borrow are among the common traits that could lead to a short squeeze.
Potential short squeeze plays gained steam in 2021 and have continued through 2022, with new traders looking for the next huge move. High short interest and a high cost to borrow are among the common traits that could lead to a short squeeze.
Potential short squeeze plays gained steam in 2021 and have continued through 2022 with new traders looking for the next huge move. High short interest and a high cost to borrow are among the common traits that could lead to a short squeeze.
U.S. stocks traded slightly higher, with the Nasdaq Composite gaining around 70 points on Tuesday. Here are some big stocks recording losses in today’s session.
Gainers OpGen, Inc. (NASDAQ: OPGN) shares surged 220% to $0.3994 after the company announced topline data from its Unyvero urinary tract infections (UTI) clinical trial.
